This “Vascular endothelial growth factor receptor-2 antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Vascular endothelial growth factor receptor-2 antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Vascular endothelial growth factor receptor-2 antagonists Understanding
Vascular endothelial growth factor receptor-2 (VEGFR-2/KDR/Flk-1) is a high-affinity receptor for vascular endothelial growth factor-A (VEGF-A), and mediates most of the endothelial growth and survival signals from VEGF-A. VEGFR-2 has a typical tyrosine kinase receptor structure with seven immunoglobulin (Ig)-like domains in the extracellular region, as well as a long kinase insert in the tyrosine kinase domain. It utilizes a unique signaling system for DNA synthesis in vascular endothelial cells, i.e. a phospholipase C gamma-protein kinase C-Raf-MAP kinase pathway. Although VEGF-A binds two receptors, VEGFR-1 and -2, a newly isolated ligand VEGF-E (Orf-virus-derived VEGF) binds and activates only VEGFR-2.
Report Highlights
This segment of the Vascular endothelial growth factor receptor-2 antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular endothelial growth factor receptor-2 antagonists Emerging Drugs
Nintedanib: Boehringer Ingelheim
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being Pirfenidone) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. As a chemotherapeutic agent for NSCLC, nintedanib, in combination with Docetaxel, is reserved for patients who have tried and failed first-line chemotherapeutic options. The drug is being evaluated in phase III stage of clinical trials to treat colorectal and ovarian cancer.
Lenvatinib: Eisai
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers.
This segment of the report provides insights about the different Vascular endothelial growth factor receptor-2 antagonists drugs segregated based on following parameters that define the scope of the report.
There are approx. 25+ key companies which are developing the Vascular endothelial growth factor receptor-2 antagonists. The companies which have their Vascular endothelial growth factor receptor-2 antagonists drug candidates in the most advanced stage, i.e. Phase III include, Boehringer Ingelheim.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Vascular endothelial growth factor receptor-2 antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vascular endothelial growth factor receptor-2 antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular endothelial growth factor receptor-2 antagonists drugs.
Geography Covered
- Global coverage
Vascular endothelial growth factor receptor-2 antagonists Understanding
Vascular endothelial growth factor receptor-2 antagonists: Overview
Vascular endothelial growth factor receptor-2 (VEGFR-2/KDR/Flk-1) is a high-affinity receptor for vascular endothelial growth factor-A (VEGF-A), and mediates most of the endothelial growth and survival signals from VEGF-A. VEGFR-2 has a typical tyrosine kinase receptor structure with seven immunoglobulin (Ig)-like domains in the extracellular region, as well as a long kinase insert in the tyrosine kinase domain. It utilizes a unique signaling system for DNA synthesis in vascular endothelial cells, i.e. a phospholipase C gamma-protein kinase C-Raf-MAP kinase pathway. Although VEGF-A binds two receptors, VEGFR-1 and -2, a newly isolated ligand VEGF-E (Orf-virus-derived VEGF) binds and activates only VEGFR-2.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Vascular endothelial growth factor receptor-2 antagonists R&D. The therapies under development are focused on novel approaches for Vascular endothelial growth factor receptor-2 antagonists.
Vascular endothelial growth factor receptor-2 antagonists Emerging Drugs Chapters
This segment of the Vascular endothelial growth factor receptor-2 antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Vascular endothelial growth factor receptor-2 antagonists Emerging Drugs
Nintedanib: Boehringer Ingelheim
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being Pirfenidone) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. As a chemotherapeutic agent for NSCLC, nintedanib, in combination with Docetaxel, is reserved for patients who have tried and failed first-line chemotherapeutic options. The drug is being evaluated in phase III stage of clinical trials to treat colorectal and ovarian cancer.
Lenvatinib: Eisai
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers.
Vascular endothelial growth factor receptor-2 antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Vascular endothelial growth factor receptor-2 antagonists drugs segregated based on following parameters that define the scope of the report.
Major Players working on Vascular endothelial growth factor receptor-2 antagonists
There are approx. 25+ key companies which are developing the Vascular endothelial growth factor receptor-2 antagonists. The companies which have their Vascular endothelial growth factor receptor-2 antagonists drug candidates in the most advanced stage, i.e. Phase III include, Boehringer Ingelheim.
Phases
This report covers around 25+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Vascular endothelial growth factor receptor-2 antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Vascular endothelial growth factor receptor-2 antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vascular endothelial growth factor receptor-2 antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular endothelial growth factor receptor-2 antagonists drugs.
Vascular endothelial growth factor receptor-2 antagonists Report Insights
- Vascular endothelial growth factor receptor-2 antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Vascular endothelial growth factor receptor-2 antagonists Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
- How many companies are developing Vascular endothelial growth factor receptor-2 antagonists drugs?
- How many Vascular endothelial growth factor receptor-2 antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular endothelial growth factor receptor-2 antagonists?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vascular endothelial growth factor receptor-2 antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Vascular endothelial growth factor receptor-2 antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Boehringer Ingelheim
- Eisai
- Advenchen Laboratories
- AiViva BioPharma
- Deciphera Pharmaceuticals
- Mirati Therapeutics
- HUTCMED
- Pfizer
- Aerie Pharmaceuticals
- Xspray Pharma
- Ascendis Pharma
- Lynkcell
- PharmAbcine
- Jiangsu Hengrui Medicine
- Chipscreen Biosciences
- Ocular Therapeutix
- Roche
- Bayer
- Metagone Biotech
- Bristol-Myers Squibb
- Akeso Biopharma
- Clearside Biomedical
- ZAI Lab
- Wayshine Biopharma
- Henlix Biotech
Key Products
- Nintedanib
- Lenvatinib
- Catequentinib
- OTX-TKI
- MG D 1609
- BAY-57-9352
- Lucitanib
- ZL-2301
- HLX06
- WSD 1227
- Pazopanib intravitreal
- AK 109
- CS-2164
- CLS 1002
- AIV 007
- SHR 1020
- Ripretinib
- Sitravatinib
- Olinvacimab
- LYN 00101
- TransCon VEGF-TKI
- Surufatinib
- Axitinib
- Axitinib implant
- Sorafenib nanoparticle formulation
Table of Contents
IntroductionExecutive Summary
Vascular endothelial growth factor receptor-2 antagonists: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Vascular endothelial growth factor receptor-2 antagonists - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
Nintedanib: Boehringer Ingelheim
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
ZL-2301: ZAI Lab
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Lenvatinib - AiViva BioPharma
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
TransCon VEGF-TKI: Ascendis Pharma
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Vascular endothelial growth factor receptor-2 antagonists Key Companies
Vascular endothelial growth factor receptor-2 antagonists Key Products
Vascular endothelial growth factor receptor-2 antagonists- Unmet Needs
Vascular endothelial growth factor receptor-2 antagonists- Market Drivers and Barriers
Vascular endothelial growth factor receptor-2 antagonists- Future Perspectives and Conclusion
Vascular endothelial growth factor receptor-2 antagonists Analyst Views
Vascular endothelial growth factor receptor-2 antagonists Key Companies
AppendixList of Tables
Table 1 Total Products for Vascular endothelial growth factor receptor-2 antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Vascular endothelial growth factor receptor-2 antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Boehringer Ingelheim
- Eisai
- Advenchen Laboratories
- AiViva BioPharma
- Deciphera Pharmaceuticals
- Mirati Therapeutics
- HUTCMED
- Pfizer
- Aerie Pharmaceuticals
- Xspray Pharma
- Ascendis Pharma
- Lynkcell
- PharmAbcine
- Jiangsu Hengrui Medicine
- Chipscreen Biosciences
- Ocular Therapeutix
- Roche
- Bayer
- Metagone Biotech
- Bristol-Myers Squibb
- Akeso Biopharma
- Clearside Biomedical
- ZAI Lab
- Wayshine Biopharma
- Henlix Biotech